IREF v. Pfizer

VERDICT

Trial
11/07/08 – 12/22/08

Summary

The plaintiffs’ trade secret misappropriation claims arise out of Coronary Artery Bypass Graft (CABG) clinical drug trials for Bextra, a second generation COX-2 inhibitor.

According to plaintiff non-profit Ischemia Research & Education Foundation (IREF), a proposed contract provided that Pfizer could have productive access to IREF's EPI1 and EPI2 adverse events databases for a CABG drug trial. However, Pfizer never signed the contract. Instead, the plaintiff said, Pfizer hired an IREF employee, who provided parts of the databases for Pfizer's use.

IREF sought $55M in direct damages.

Pfizer denied that it had conspired with the IREF employee, or stole any trade secret, but suggested that the employee had his own dispute with IREF, and might have acted based upon that dispute.

The jury awarded IREF damages of over $38M for misappropriation of trade secrets.

Outcome

Damages: 38,700,000

Sessions

AM Session
Openings
3 Chapters
PM Session
Not in Session
0 Chapters
NOV
7
AM Session
Not in Session
0 Chapters
PM Session
Not in Session
0 Chapters
NOV
11
PM Session
Not in Session
0 Chapters
DEC
9
AM Session
Not in Session
0 Chapters
PM Session
Not in Session
0 Chapters
DEC
12
PM Session
Judge Motion Ruling
2 Chapters
DEC
19
PM Session
In Session - No Content Available
0 Chapters
DEC
22

Recording Disclaimer: This proceeding was recorded in full except noted sections that were not recorded.

Suggest a Trial

Want to see a trial that you don't see in our list of upcoming trials?

Suggest a Case

CVN Essentials

The most important and informative moments of each trial

CVN Essentials

Video Library

Unlimited access to thousands of hours of past coverage of high stakes civil litigation

Video Library

  • Follow Us
  • Contact Us
  • 4901 Olde Towne Parkway
  • Suite 100
  • Marietta, GA 30068
  • 877-834-8627
  • 404-935-0321

Copyright 2024 Courtroom Connect.